TB-500: Thymosin Beta-4 Fragment — Scientific Analysis
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Scientific guide to TB-500: mechanism of action via Thymosin Beta-4, actin modulation, angiogenesis and tissue regeneration. Studies and applications described in literature.
Mechanism of Action
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), specifically the LKKTETQ sequence (amino acids 17–23). Tβ4 is a ubiquitous 43-amino acid protein abundant in platelets, injured tissues, and proliferating cells. TB-500 exerts regenerative effects via regulation of actin G polymerization and wound healing pathway activation.
G-Actin Sequestration and Cell Mobility
TB-500 (and intact Tβ4) binds actin G monomers in a 1:1 ratio, regulating the balance between globular (G) and filamentous (F) actin. This increases mobility of keratinocytes, fibroblasts, and endothelial cells — a fundamental step in cell migration during tissue repair.
Anti-inflammatory and Anti-apoptotic Pathway Activation
Tβ4 activates the ILK (Integrin-Linked Kinase) → Akt → anti-apoptotic NF-κB pathway. Cardiac studies demonstrate reduction of cardiomyocyte apoptosis post-infarction. Simultaneously, it downregulates TNF-α and IL-6 in acute inflammation models.
Angiogenesis and Tissue Remodeling
TB-500 upregulates VEGF and laminin receptors, promoting new vessel formation and extracellular matrix deposition. In cutaneous wound models, it accelerates re-epithelialization and wound contraction. In musculoskeletal tissue, it facilitates satellite cell recruitment for muscle repair.
- •Active fragment of Thymosin Beta-4 with main mechanism via G-actin
- •Pleiotropic action: anti-inflammatory, angiogenic, and regenerative simultaneously
- •Robust animal models; human data still in early phase
Applications Described in Literature
Musculoskeletal Injury Repair
Preliminary evidenceAnimal models of muscle, tendon, and ligament injury demonstrate accelerated repair with Tβ4/TB-500. Rodent studies with Achilles tendon and ACL injury show increased type I collagen and improved tensile strength. Literature describes protocols of 2.0–2.5 mg twice weekly in pre-clinical studies.
Cardioprotection and Cardiac Regeneration
Preliminary evidenceThis is the area with the most data on Tβ4. Studies in murine myocardial infarction models show reduced infarct area, increased cardiomyocyte survival, and improved ejection fraction. Mechanism involves cardiac progenitor cell activation and ILK/Akt pathway. PHAST clinical trial (phase I/II) in infarction patients evaluated intact Tβ4 IV.
Wound Healing and Corneal Repair
Moderate evidenceTopical use of Tβ4 in cutaneous wounds and cornea (dry eye, corneal ulcers) is the application with the most clinical evidence. Phase II clinical trial (ReVOLT) evaluated Tβ4 eye drops for dry eye. In chronic cutaneous wounds (diabetic, venous), literature describes 35–42% faster re-epithelialization in controlled models.
Relevant Studies
3 curated studies · 2004–2012
Peer-reviewed evidence with PMID verifiable on PubMed
Thymosin beta-4 and its derivatives: new perspectives in regenerative medicine
Goldstein AL, Hannappel E, et al. · Expert Opinion on Biological Therapy
Comprehensive review of Tβ4 and derivatives in regenerative medicine: wound healing, cardioprotection, and neurological repair. Highlights G-actin and ILK/Akt mechanisms as main pathways.
Thymosin beta-4 reduces infarct size and improves cardiac function after myocardial infarction
Bock-Marquette I, Saxena A, et al. · Nature
Classic Nature study: Tβ4 activates ILK and promotes cardiomyocyte survival post-infarction in murine models. 30% reduction in infarct area and improved cardiac function.
Thymosin beta-4 promotes angiogenesis, wound healing, and hair follicle development
Philp D, Kleinman HK · Annals of the New York Academy of Sciences
Review of pre-clinical data on Tβ4 in angiogenesis, wound healing, and follicular development. Documents VEGF upregulation and endothelial cell mobility.
Latest literature review: 2026-04 · PubMed
FAQ
What is TB-500?
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), specifically the Ac-LKKTETQ fragment. Tβ4 is an endogenous protein involved in actin polymerization, cell migration, angiogenesis and tissue repair processes, as described in multiple preclinical studies.
Are TB-500 and BPC-157 complementary?
In preclinical literature, Tβ4 and BPC-157 act through distinct but potentially synergistic mechanisms: Tβ4 modulates actin and progenitor cell mobilization, while BPC-157 acts via NO and VEGF. Combination studies in animal models are limited and extrapolation to humans requires professional assessment.
Coming Soon
The premium guide for TB-500 will be available soon.
Already available: Ipamorelin, BPC-157, Semaglutide, GHK-Cu
View Available Peptides →⚠️ Exclusively educational content. Does not constitute medical prescription.